Skip to main content
Macrogen, Inc. logo

Macrogen, Inc. — Investor Relations & Filings

Ticker · 038290 ISIN · KR7038290003 KO Professional, scientific and technical activities
Open in API
Filings indexed 353 across all filing types
Latest filing 2020-03-03 Proxy Solicitation & In…
Country KR South Korea
Listing KO 038290

About Macrogen, Inc.

https://www.macrogen.com/en/main

Macrogen, Inc. is a biotechnology company specializing in precision medicine and genomic analysis. It provides a comprehensive suite of services, including Next-Generation Sequencing (NGS), Sanger sequencing, and spatial transcriptome analysis, to a global client base. The company's core activities are focused on three key areas: Research and Data Analysis, offering fast and accurate genomic services to the scientific community; Clinical Diagnostics, advancing disease prediction through the integration of genomic and medical big data; and Personal Healthcare, providing genetic tests for wellness, nutrition, and disease risk assessment. By combining its extensive genomic expertise with big data and AI, Macrogen aims to deliver hyper-personalized healthcare solutions and innovate in the field of future medicine.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Macrogen. It details the date, location, and specific agenda items (approval of financial statements, appointment of directors, and changes to business objectives). This type of document is a standard proxy solicitation material sent to shareholders to inform them of upcoming meeting details and to request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2020-03-03 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with many other companies' meetings, citing internal audit schedules and operational requirements. Since this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves (AGM-R) or a proxy statement (PSI), it falls under the general regulatory filing category.
2020-03-03 Korean
기타경영사항(특허권취득)(자율공시)(암줄기세포 특이적 바이오마커)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) by Macrogen regarding the acquisition of a patent for 'Cancer Stem Cell-Specific Biomarkers'. It details the patent name, content, holder, and utilization plan. Since this is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, governance, or other specific categories, it is classified as a general regulatory filing.
2020-02-17 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (Macrogen) announcing a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement for listed companies in Korea (DART system) to provide preliminary financial results before the final audited report is released. Since it provides key financial highlights and reasons for the change, it fits the definition of an Earnings Release (ER). FY 2019
2020-02-13 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 98% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the termination of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This involves the company's management of its own shares, specifically the termination of a buyback trust, which falls under the category of 'Transaction in Own Shares'.
2020-01-10 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 95% confidence The document is a '신탁계약해지결과보고서' (Report on the Termination of a Trust Agreement) filed with the Financial Supervisory Service (FSS) in South Korea. It details the termination of a trust contract used for share buybacks, including the final status of treasury shares held. This type of filing is a specific regulatory disclosure regarding corporate capital and share management, which falls under the 'Transaction in Own Shares' category as it reports the conclusion of a share repurchase program.
2020-01-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.